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The diagnosis of metastatic renal cell carcinoma (RCC) in cytol-
ogy specimens may be difficult to confirm on the basis of cyto-
morphology alone. Often, immunohistochemistry serves as an im-
portant adjunct in confirming this diagnosis. Recently, PAX2 was
shown to be useful in this regard. In this study, we sought to com-
pare the utility of PAX8 to that of PAX2 immunohistochemistry in
the diagnosis of RCC in cytology specimens. First, we verified the
performance of PAX8 immunohistochemistry on a tissue microar-
ray (TMA) composed of 54 cases of RCC; PAX8 immunoreactivity
was seen in at least 10% of the tumor cells in all cases. Next, we
applied PAX8 immunohistochemistry to cell block sections pre-
pared from 24 cases of RCC, obtained from fine-needle aspirates
and effusion specimens. PAX2 immunohistochemistry was per-
formed for comparison. Immunopositivity was defined as the pres-
ence of nuclear staining in at least 10% of tumor cell nuclei.
Immunoreactivity for PAX8 and PAX2 was seen in 21 (88%) and
20 (83%) of the 24 cases, respectively. The presence of either
PAX8 or PAX2 immunostaining was present in 22 of 24 cases,
thus showing a total sensitivity of 92%. Overall, the results indi-
cate that PAX8 and PAX2 are diagnostically useful adjuncts in
confirming the diagnosis of RCC in cytology specimens. Diagn.
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In the United States, renal cancer accounts for approxi-
mately 4% of malignancies and is predicted to cause
approximately 13,000 cancer-related deaths in 2010.1 The
majority of renal cancers are renal cell carcinomas
(RCC), a histologically diverse entity encompassing vari-
ous subtypes including clear cell, papillary, chromophobe,
sarcomatoid, and Xp11.2 translocation RCCs.2 Metastases
secondary to RCC are usually seen in patients with
known high-grade, high-stage disease (i.e., AJCC stage
T3). However, RCC occasionally presents initially as a
metastasis or malignant effusion.3–5 While RCC is an un-
usual source of metastatic carcinoma, it is especially im-
portant to differentiate RCC from other carcinomas as
RCC represents one of the most aggressive genitourinary
malignancies. Confirming RCC as the source of metasta-
sis enables for appropriate pathologic staging thereby
facilitating optimal therapeutic intervention.6 While RCCs
exhibit distinctive cytomorphologic features in primary as
well as metastatic deposits,7 the lack of perfect specificity
of these features underscores the need for adjuncts such
as cytogenetics and immunohistochemistry in the diagno-
sis and subclassification of RCCs.8–11
PAX8 and PAX2 are both members of the paired box
gene (PAX) family of transcription factors that serve im-
portant roles in early metazoan development. Specifically,
PAX2 has been most intensively studied in the kidney
where it has been shown to play a crucial role in renal
development.12 In addition, PAX8 is critical in renal and
thyroid development. Recently, the expression of both has
been reported in the female genital tract.13–16 Accordingly,
the use of these two markers as immunohistochemical
adjuncts in establishing the site of origin for carcinomas is
becoming increasingly appreciated. For instance, PAX2 and
PAX8 expression has been demonstrated in malignant neo-
plasms of Müllerian and renal origin in surgically resected
specimens.14–23 Recently, the diagnostic utility of PAX8
immunohistochemistry in identifying Müllerian carcinomas
in fine needle aspiration (FNA) and effusion specimens has
been reported by several groups.24–26
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There are limited reports that investigate the role of
PAX2 immunohistochemistry in the diagnosis of RCC in
cytology.19,27 In the reports by Gokden et al. and Wasco
et al., PAX2 immunoreactivity was observed in 61% and
79% of RCCs, respectively. As there are no reports to
date that examine the role of PAX8 in the cytologic diag-
nosis of RCC, we sought to investigate and compare the
diagnostic utility of PAX8 and PAX2 in our study.
Methods
The study was approved by the University of Michigan
Institutional Review Board. The electronic pathology
database was searched from 2000 to 2010 for cases in
which a cytologic diagnosis of RCC was rendered in
patients with histologically confirmed disease based on
resections of the primary renal tumor and/or biopsies of
metastases. Twenty-four cases with sufficient material in
the cell block preparations were selected for immunohis-
tochemical analysis. Additionally, we utilized a tissue
microarray (TMA) that consisted of 54 cases of primary
RCC: 30 clear cell RCCs; 17 papillary RCCs; and 7 chro-
mophobe RCCs.
Immunohistochemistry for PAX2 and PAX8 was
performed as previously reported.26 Essentially, 4-lm
unstained sections were prepared from the TMA and cell
blocks, deparaffinized, and immunostained after antigen
retrieval in 0.01M citrate buffer, pH 6.0 (DAKO, Carpin-
teria, CA). Immunohistochemistry was performed using
the rabbit polyclonal anti-PAX2 (1:100 dilution; Invitro-
gen, Camarillo, CA) and rabbit polyclonal anti-PAX8
(1:200 dilution; Protein Tech, Chicago, IL) antibodies
along with appropriate controls. The EnVision+ System
for use with rabbit primary antibodies (DAKO, Carpinte-
ria, CA) was used as the secondary antibody.
TMA immunohistochemistry results for PAX8 were
reviewed (LPK) and subdivided into three groups based
on the proportion of cells exhibiting nuclear immunoreac-
tivity: minimal or no positivity (<10% of cells), focal pos-
itivity (10–50% of cells), or diffuse positivity (>50% of
cells). Each immunostained slide prepared from the cell
blocks were reviewed (SMK and MHR) and considered
positive for PAX8 or PAX2 if at least 10% of tumor cells
exhibited nuclear staining.
Results
To determine the efficacy of PAX8 immunohistochemistry
in detecting RCCs in histologic material, a TMA consist-
ing of 54 RCCs was initially examined. Specifically, there
were 30, 17, and 7 cases of clear cell, papillary, and chro-
mophobe RCCs, respectively (Table I). In 53 (98%) of
54 cases, greater than 50% of the tumor cells displayed
nuclear immunoreactivity for PAX8 (Fig. 1). In the
remaining case of a type 1 papillary RCC, at least 10% of
the tumor cells were PAX8(+).
Next, we analyzed a series of 24 cytology specimens
representing three cases of primary RCC and 21 cases of
metastatic RCC. For FNA specimens of the primary renal
tumors, the follow-up histologic diagnoses were clear cell
RCC in two cases and papillary RCC in one case. Of the
21 cases of metastatic RCC, 17 and 4 were FNA and
effusion specimens, respectively (Table II). In these cases,
the associated histologic diagnoses of primary tumors
and/or metastatic deposits were clear cell RCC in
12 cases, papillary RCC in three cases, papillary RCC
with sarcomatoid transformation in one case, pure sarco-
matoid RCC in one case, and RCC of unknown subtype
in four cases.
We first examined immunohistochemistry for PAX8 in
the 24 cytology cases of RCC. The results are summar-
ized in Table II. PAX8 positivity was seen in 21 (88%)
of 24 cases (Fig. 2). In 17 of the 21 PAX8(+) cases,
greater than 50% of the tumor cells exhibited nuclear im-
munoreactivity for PAX8. In the other four PAX8(+)
cases, between 10% and 50% of the tumor cells were
immunopositive. In the remaining three cases including
two cases of clear cell RCC and one case of pure sarco-
matoid RCC, all of the tumor cells were PAX8(). For
comparison, these cases were also immunostained for
PAX2. PAX2 positivity was seen in 20 (83%) of 24 cases
(Fig. 2). In 14 of these 20 PAX2(+) cases, over 50% of
the tumor cells were PAX2(+). In the other six PAX2(+)
cases, at least 10% of the tumor cells were immunoreac-
tive for PAX2. Cases that were negative for PAX2
included two cases of clear cell RCC, one case of pure
sarcomatoid RCC, and one RCC of unknown subtype. In
these four cases, none of the tumor cells exhibited immu-
noreactivity for PAX2. Overall, immunoreactivity for
both PAX8 and PAX2 was seen in 19 (79%) of 24 cases.
Finally, positivity for either of the two markers was
detected in 22 (92%) of the 24 cases. Specifically, there
were two PAX2() RCCs that were PAX8(+). Con-
versely, there was one PAX8() RCC that stained posi-
tively for PAX2.










Clear cell RCC 0 0 30 30
Papillary RCC 0 1 16 17
Type 1 0 1 12 13
Type 2 0 0 4 4
Chromophobe RCC 0 0 7 7
Total 0 1 53 54
RCC, renal cell carcinoma.
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Discussion
PAX8 and PAX2 play important roles as transcription
factors during the organogenesis of the kidney.12 In the
adult kidney, nuclear expression of PAX8 has been dem-
onstrated by immunohistochemistry in the parietal cells of
Bowman’s capsule and all segments of the renal
tubules.23 This expression profile partially overlaps with
that of PAX2 in non-neoplastic renal parenchyma; nuclear
immunoreactivity has been demonstrated in the parietal
cells, distal convoluted tubules, loops of Henle, and col-
lecting duct.28 Furthermore, in these reports, PAX8 and
PAX2 expression was shown to be maintained in carcino-
mas derived from the renal tubule epithelium, specifically
RCCs. As there are no studies to date that have investi-
gated the use of PAX8 immunohistochemistry in meta-
static renal neoplasms in diagnostic cytology, we sought
to test our hypothesis that PAX8 immunostaining could
serve as a useful adjunct in the diagnosis of RCCs in
cytology specimens.
We first validated the use of PAX8 immunohistochem-
istry on a TMA composed of 54 primary RCCs and found
that PAX8 was expressed all of the RCCs tested, specifi-
cally, those of the clear cell, papillary, and chromophobe
subtypes. This is in agreement with the findings reported
by Tong et al., who detected PAX8 expression in a high
proportion of clear cell, papillary, and chromophobe
RCCs.23
We next examined PAX8 expression in 24 cytology
specimens and demonstrated that the majority (88%) of
RCCs exhibited positive immunostaining for PAX8. The
Fig. 1. PAX8 immunohistochemistry reveals nuclear staining in a various subtypes of renal cell carcinoma (RCC) on a tissue microarray (TMA).
A: Clear cell RCC, 3400. B: Chromophobe RCC, 3400. C: Papillary RCC, type 1, 3400. D: Papillary RCC, type 2, 3400. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
Table II. PAX2 and PAX8 Immunostaining in Fine-Needle Aspiration
Biopsy Specimens of RCC
FNA Site PAX2 PAX8 Associated Histologic Diagnosis
Hilar mass   Clear cell RCC
Subcarinal mass + + Clear cell RCC
Paratracheal LN + + Papillary and sarcomatoid RCC
Paratracheal LN + + Clear cell RCC
Left renal mass + + Clear cell RCC
Pericardial fluid + + Papillary RCC
Pancreatic tail   Sarcomatoid RCC
Right renal mass + + Clear cell RCC
Right renal mass + + Papillary RCC
Pancreatic mass + + Clear cell RCC
Paratracheal LN + + Clear cell RCC
Para-renal LN + + Clear cell RCC
Pancreas + + RCC, unknown subtype
Adrenal + + Clear cell RCC
Thyroid + + Clear cell RCC
Right neck + + Clear cell RCC
Pleural fluid  + RCC, unknown subtype
Left neck + + Papillary RCC
Lung, LUL + + Clear cell RCC
Vertebral mass + + RCC, unknown subtype
Left peri-aortic LN +  Clear cell RCC
Ascitic fluid + + RCC, unknown subtype
Right C-2 mass + + Papillary RCC
Pleural fluid  + Clear cell RCC
RCC, renal cell carcinoma; LUL, left upper lobe; LN, lymph node.
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majority of these were metastases; therefore, PAX8 can
serve as a valuable immunohistochemical adjunct in con-
firming a metastatic tumor as RCC. Of note, one of the
metastatic RCC cases in our cohort involved the thyroid
gland. Caution should be exercised in interpreting PAX8
immunohistochemistry in this setting as non-neoplastic
and neoplastic thyroid follicular cells are often positive
for PAX8. In contrast, as thyroid follicular cells do
not display immunoreactivity for PAX2,29 this marker
would serve to discriminate metastatic RCC from epithe-
lial cells of thyroid origin. In addition, three of the 24
cytology cases were FNAs of the primary renal tumor. In
this setting, caution should also be exercised in interpret-
ing the PAX8 immunostain as PAX8 immunoreactivity
can be seen in benign renal tubular cells and in tumor
cells.23
Next, for comparison, we also examined our cytology
case cohort for PAX2 expression. We found that 20 of
the 24 cytology cases of RCC were positive for PAX2
for an overall sensitivity of 83% comparable to that for
PAX8. This is concordant with the results published
by Wasco et al. who demonstrated a 79% PAX2 positiv-
ity rate in RCCs.27 Another study by Gokden et al.
reported a lower PAX2 positivity rate of 61% in RCCs.19
This underscores the notion that PAX8 represents a
useful additional marker to confirm a metastatic RCC,
especially in the scenario where PAX2 fails to highlight
the tumor cells.
Overall, the data stemming from our cytology case
cohort compare similarly to a prior study examining the
utility of PAX8 immunohistochemistry in the diagnosis of
primary or metastatic RCCs in surgically resected speci-
mens.23 Our results indicate that PAX8 is as sensitive as
or more sensitive than other commonly used markers in
confirming a diagnosis of RCC. CD10 is positive in 82%
of clear cell RCCs and 59% of papillary RCCs30 which
Fig. 2. PAX8 and PAX2 immunohistochemistry reveals nuclear staining in the majority of RCCs in cell block preparations from cytology specimens.
A–C: Clear cell RCC, 3600. D–F: Papillary RCC, 3400. G–I: Sarcomatoid RCC, 3400. Hematoxylin and eosin stained sections are shown in A, D,
and G. PAX8 immunostains are displayed in B, E, and H. PAX2 immunostains are shown in C, F, and I. Nuclear immunoreactivity for both markers
are observed in the clear cell and papillary RCC (B, C, E, F) but not in the case of sarcomatoid RCC (H, I). [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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falls below our observed sensitivity for PAX8 (88%).
Likewise, EMA shows lower sensitivity for clear cell
RCC or papillary RCC (77% and 67%, respectively).30
Wasco and Pu reported a sensitivity of 56% for RCC anti-
gen and 73% for gamma-H2AX antibodies for detecting
RCC in cytology specimens.27,31 Furthermore, RCC anti-
gen shows highest sensitivity for papillary RCCs (95%),
but shows only 72% sensitivity for clear cell RCC, the
most common subtype.32
The specificity for PAX8 and PAX2 in diagnostic
cytology has been previously reported based on studies
that examined metastatic carcinomas in predominantly
effusion specimens and a limited number of FNAs.
Importantly, neither PAX8 nor PAX2 expression has
been observed in metastatic adenocarcinomas from lung,
breast, pancreaticobiliary, and gastrointestinal tract pri-
maries.19,25,26 Nonetheless, it should be noted that PAX8
and PAX2 expression is not completely specific for RCC.
Apart from RCC, PAX8 immunoreactivity can be
observed in carcinomas of Müllerian and thyroid ori-
gin.24–26 Of note, Müllerian papillary serous carcinoma
and papillary thyroid carcinoma can mimic papillary RCC
due to their characteristic papillary architectural features.
Because all three entities are often PAX8(+) and PAX2
expression can be seen in a subset of serous carcinomas,26
neither PAX8 nor PAX2 would be specific for RCC in
this context. To distinguish between these three entities,
additional immunohistochemical stains would provide
valuable diagnostic aid. Specifically, Müllerian papillary
serous carcinoma would be expected to be immunoreac-
tive for one or more of the following: WT-1; ER; and
PR. In contrast, papillary thyroid carcinomas and RCCs
would be negative for these markers. In addition, thyro-
globulin and TTF-1 would serve to differentiate papillary
thyroid carcinoma from serous carcinoma and RCC. Next,
Müllerian clear cell carcinomas can mimic clear cell
RCCs owing to the delicate, vacuolated cytoplasm and
prominent nucleoli frequently observed in both. As PAX8
and PAX2 expression can be seen in a subset of the for-
mer,13,18 these markers would not be helpful in differenti-
ating clear cell RCC from Müllerian clear cell carcinoma.
Again, additional immunohistochemical markers such as
cytokeratin 7 (CK7) and RCC antigen can be helpful in
this regard.18 Specifically, a CK7() immunophenotype
would favor clear cell RCC whereas CK7-positivity
would be more consistent with a Müllerian clear cell
carcinoma. Furthermore, demonstrating immunoreactivity
for RCC antigen would support a diagnosis of RCC.
In conclusion, our study demonstrates that both PAX8
and PAX2 are useful markers for identifying metastatic
RCC in cytology specimens. While PAX8 shows a slight
increase in sensitivity over PAX2 in RCCs, the highest
sensitivity and therefore greatest utility lies in using both
markers for confirming a diagnosis of RCC.
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